What question did this study set out to answer?

To establish an adaptive platform trial comparing the effectiveness of six non-opiate medications for painful cryptogenic sensory polyneuropathy.

June 22, 2022RRNMF Neuromuscular JournalOpen Access

Determining Best or Inferior Drug(s) Using an Adaptive Platform for Cryptogenic Sensory Polyneuropathy

View Full Paper

Ask AI

Bookmark

To establish an adaptive platform trial comparing the effectiveness of six non-opiate medications for painful cryptogenic sensory polyneuropathy.
Open-label, pragmatic comparative effectiveness trial integrating findings from a prior four-drug trial using adaptive statistical modeling.
Targeted individuals diagnosed with cryptogenic sensory polyneuropathy based on established clinical criteria after excluding secondary causes like diabetes.
Evaluated clinical barriers to diagnosis and therapeutic implementation across diverse patient cohorts.
Cryptogenic sensory polyneuropathy accounts for at least 25% of all referred peripheral neuropathy cases across tertiary clinics in North and South America.
Pain presents as the primary symptom in 70% to 80% of affected individuals, typically starting in distal lower extremities and spreading to upper extremities over an average of five years.
Patients present as a clinically homogeneous group across sexes and ethnicities, supporting standardized diagnostic and adaptive pharmacological testing strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Pragmatic trial evaluates non-opiate medications in cryptogenic sensory polyneuropathy, highlighting comparative effectiveness strategies to optimize neuropathic pain management.

Cite This Study

Barohn et al. (2022) studied this question.

synapsesocial.com/papers/6a74bbbb96d04a2f43f554be https://doi.org/10.17161/rrnmf.v3i2.18133

View Full Paper

Ask AI

Bookmark

Implication

Pragmatic trial evaluates non-opiate medications in cryptogenic sensory polyneuropathy, highlighting comparative effectiveness strategies to optimize neuropathic pain management.

Determining Best or Inferior Drug(s) Using an Adaptive Platform for Cryptogenic Sensory Polyneuropathy

Key Points

Discussion

Implication

Cite This Study

Determining Best or Inferior Drug(s) Using an Adaptive Platform for Cryptogenic Sensory Polyneuropathy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider